A recent article in the journal Cancer reported that there is an association for men being treated for prostate cancer with androgen deprivation therapy (ADT) and a risk of developing blood clots. The article, written by Edhaie et al. analyzed the Surveillance, Epidemiology and End Results (SEER) –Medicare database to identify 154,611 men over the [...]
Sometimes you have a good idea and you aren't sure why others don't get on board right away. It gets frustrating for some because they realize that the idea of "if you build it, they will come" does not hold up very well in reality. In fact what becomes more true is that if you [...]
We know that both a positive family history and racial background are among the strongest epidemiological risk factors for prostate cancer. It is also recognized that the role of candidate genetic markers to prostate cancer is more difficult to identify than the identification of other cancer susceptibility genes. Despite the localization of several susceptibility loci, [...]
According to Bloomberg News Celgene Corp. said it will stop a study (Mainsail) of its blood-cancer pill Revlimid as a treatment for prostate cancer because the drug failed to help patients more than chemotherapy and steroids alone. This conclusion was drawn after the data-monitoring panel found the drug did not meet its primary goal of [...]
Amgen announced that they have published the results from their Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with non-metastatic castration-resistant prostate cancer (CRPC). The results were published in The Lancet. The study found XGEVA significantly prolonged bone metastasis-free survival, [...]